AstraZeneca Seeks FDA Approval for New Lung Cancer Treatment
FROM THE WIRE · FINANCE.YAHOO.COM
AstraZeneca PLC (US) (NYSE:AZN) is on the cusp of unlocking a new growth engine in lung cancer treatment. On September 29, Reuters reported that the company has applied to the US Food and Drug Administration for approval of ORPATHYS-TAGRISSO. But can this potential lung cancer…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishFDA approval request for a new oncology drug is market-moving for the pharma mega-cap.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01AstraZeneca applied for FDA approval of ORPATHYS-TAGRISSO on September 29.
- 02The drug, developed with HUTCHMED, targets advanced lung cancer.
- 03Phase 3 SAFFRON trial with 338 patients demonstrated efficacy in treating tumor progression.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets